Breaking News Instant updates and real-time market news.

SRNE

Sorrento Therapeutics

$3.39

-0.28 (-7.63%)

08:07
11/06/18
11/06
08:07
11/06/18
08:07

Sorrento Therapeutics says anti-CEA CAR-T shows increased OS in trial

Sorrento Therapeutics announced the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery manufactured by TriSalus Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen-positive, unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases method. The immunotherapy was delivered by means of PEDD technology, which overpowers the high pressure within solid tumors that limits the reach and efficacy of therapeutic agents. Two out of the four pancreatic cancer patients had no viable liver metastases by PET scan after treatment. After 12 months, one patient with stage IV pancreatic carcinoma still showed no evidence of liver metastases on PET imaging, and his primary pancreatic tumor was well-controlled. A second patient with stage IV pancreatic cancer also had no evidence of liver metastases six weeks after CAR-T/PEDD infusions. Median overall survival post-treatment is 8.3 months and the mean OS is 9.8 months to date. No patient suffered any severe adverse event related to the CAR-T infusions.

SRNE Sorrento Therapeutics
$3.39

-0.28 (-7.63%)

02/20/18
HCWC
02/20/18
NO CHANGE
Target $35
HCWC
Buy
Sorrento Therapeutics price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Sorrento Therapeutics to $35 following the completion of the Celularity financing. The analyst notes the FDA action date for ZTlido is up next. He reiterates a Buy rating on the shares.
02/28/18
HCWC
02/28/18
NO CHANGE
Target $38
HCWC
Buy
Sorrento price target raised to $38 after ZTlido approval at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju noted that Sorrento Therapeutics' receipt of FDA approval of ZTlido, the company's next-generation topical lidocaine product, came on schedule on the previously-announced PDUFA date of February 28. The analyst, who notes the product is entering the pain management market at a time when promotion of other topical lidocaine products "has virtually disappeared," believes ZTlido could prove to be popular and have a relatively swift commercial ramp. He raised his price target on Sorrento shares to $38 from $35 following the approval and keeps a Buy rating on the stock.
04/03/18
HCWC
04/03/18
NO CHANGE
Target $40
HCWC
Buy
Sorrento target raised to $40 after completed financing at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Sorrento Therapeutics to $40 from $38 saying the recently completed convertible note financing "provides ample runway." The company now has a sufficient cash runway to fund operations for at least the next 24 months, which removes a near-term overhang, Selvaraju tells investors in a research note. He reiterates a Buy rating on Sorrento.
06/28/18
RILY
06/28/18
INITIATION
Target $14.25
RILY
Buy
Sorrento Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Sorrento Therapeutics with a Buy rating and $14.25 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/18
11/20
12:17
11/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/18
11/20
12:16
11/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$34.13

-1.16 (-3.29%)

12:10
11/20/18
11/20
12:10
11/20/18
12:10
Options
Puts lead calls 4:1 in Boston Scientific as implied volatilities lift »

Puts lead calls 4:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

12:10
11/20/18
11/20
12:10
11/20/18
12:10
General news
U.S. equities remain under pressure »

U.S. equities remain…

AMAT

Applied Materials

$36.27

1.85 (5.37%)

12:05
11/20/18
11/20
12:05
11/20/18
12:05
Options
Applied Materials call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/20/18
11/20
12:05
11/20/18
12:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

FB

Facebook

$133.04

1.42 (1.08%)

12:02
11/20/18
11/20
12:02
11/20/18
12:02
Hot Stocks
Facebook experiencing service issues »

Visiting Facebook.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EGRX

Eagle Pharmaceuticals

$48.01

-1.36 (-2.75%)

12:01
11/20/18
11/20
12:01
11/20/18
12:01
Conference/Events
Eagle Pharmaceuticals management to meet with RBC Capital »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 02

    Dec

SDRL

Seadrill

$14.63

-1.84 (-11.17%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Seadrill falls -11.2% »

Seadrill is down -11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EROS

Eros International

$8.19

-1.16 (-12.41%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Eros International falls -12.4% »

Eros International is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 20

    Dec

LB

L Brands

$30.23

-4.3 (-12.45%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
L Brands falls -12.5% »

L Brands is down -12.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SCO

Scor ADR

$23.44

2.26 (10.67%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Scor ADR rises 10.9% »

Scor ADR is up 10.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$45.61

4.81 (11.79%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Noah Holdings rises 11.3% »

Noah Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$11.85

1.62 (15.84%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Britannia Bulk rises 16.1% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$28.44

0.7 (2.52%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX raises FY19 revenue view to $38.6B-$38.7B from $38.2B-$38.4B »

Consensus $38.44B. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX sees Q4 revenue $10B-$10.9B, consensus $10.92B »

Says guidance assumes a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

UNP

Union Pacific

$142.91

-7.74 (-5.14%)

11:55
11/20/18
11/20
11:55
11/20/18
11:55
Options
Union Pacific put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

11:53
11/20/18
11/20
11:53
11/20/18
11:53
Conference/Events
William Blair industrial technology analysts to hold a group luncheon »

Group Luncheon Meeting to…

BECN

Beacon Roofing

$28.34

0.6 (2.16%)

11:52
11/20/18
11/20
11:52
11/20/18
11:52
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:51
11/20/18
11/20
11:51
11/20/18
11:51
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
General news
U.S. sold $50 B 4-week T-bills at a 2.20% high rate »

U.S. sold $50 B 4-week…

11:43
11/20/18
11/20
11:43
11/20/18
11:43
Conference/Events
William Blair industrials & business services analysts hold dinner meeting »

Analysts hold a year-end…

BBY

Best Buy

$63.57

1.38 (2.22%)

11:42
11/20/18
11/20
11:42
11/20/18
11:42
Recommendations
Best Buy analyst commentary  »

Best Buy 'continued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.